H.C. Wainwright raised the firm’s price target on Editas Medicine (EDIT) to $5 from $3 and keeps a Buy rating on the shares following the Q2 report. The firm cites a more favorable expense trajectory for the target increase.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT: